Epigral Limited

rs,

oor- 25, P J Tower, Dalal Street, Mumbai 400 001 SYMBOL:- EPIGRAL Scrip Code: 543332 Dear Sirs, Sub.: Investors Presentation on Un-Audited Financial Results – Q2 FY26 Ref.: Regulation 30 of the S

78%

in the coming years. Q2FY2026 Result update Key Highlights Q2FY26 o Plant utilization stood at 78% vs 73% in previous quarter o Sales volume grew by 2% compared to previous quarter o QoQ Revenue dro

73%

coming years. Q2FY2026 Result update Key Highlights Q2FY26 o Plant utilization stood at 78% vs 73% in previous quarter o Sales volume grew by 2% compared to previous quarter o QoQ Revenue dropped by

2%

hlights Q2FY26 o Plant utilization stood at 78% vs 73% in previous quarter o Sales volume grew by 2% compared to previous quarter o QoQ Revenue dropped by 4% to ₹ 589 Cr on account of drop in realizat

4%

in previous quarter o Sales volume grew by 2% compared to previous quarter o QoQ Revenue dropped by 4% to ₹ 589 Cr on account of drop in realizations in few of the products o EBITDA margin stood at 23%

₹ 589

vious quarter o Sales volume grew by 2% compared to previous quarter o QoQ Revenue dropped by 4% to ₹ 589 Cr on account of drop in realizations in few of the products o EBITDA margin stood at 23% vs 27% in

23%

4% to ₹ 589 Cr on account of drop in realizations in few of the products o EBITDA margin stood at 23% vs 27% in Q1FY26 on account of drop in realizations and lower utilization H1FY26 o Plant utilizat

27%

₹ 589 Cr on account of drop in realizations in few of the products o EBITDA margin stood at 23% vs 27% in Q1FY26 on account of drop in realizations and lower utilization H1FY26 o Plant utilization sto

75%

FY26 on account of drop in realizations and lower utilization H1FY26 o Plant utilization stood at 75% vs 83% in H1FY25 o Sales volume dropped in H1FY26 majorly on account of off season for few of the p

83%

account of drop in realizations and lower utilization H1FY26 o Plant utilization stood at 75% vs 83% in H1FY25 o Sales volume dropped in H1FY26 majorly on account of off season for few of the products

6%

son for few of the products and we expect sales volume to improve in H2FY26 o Revenue dropped by 6% to ₹ 1,204 Cr on account of drop in sales volume o EBITDA margin stood at 25% vs 28% in H1FY25 on a

₹ 1,204

r few of the products and we expect sales volume to improve in H2FY26 o Revenue dropped by 6% to ₹ 1,204 Cr on account of drop in sales volume o EBITDA margin stood at 25% vs 28% in H1FY25 on account of dr

“Responsible Care Certificate 33% 30% 5 Year Revenue CAGR (FY25) 5 Year EBITDA CAGR (FY25) 0.3x 25% Debt to Equity (FY25) ROCE (FY25) Revenue (₹ Crore) 1,555 831 2,196 1,936 2,565”

Founded

1

Employees

1

Certified

1

Manufacturing facility

1

Integration

1

New Value Chains

1

Certified

Responsible Care Certificate 33% 30% 5 Year Revenue CAGR (FY25) 5 Year EBITDA CAGR (FY25) 0.3x 25% Debt to Equity (FY25) ROCE (FY25) Revenue (₹ Crore) 1,555 831 2,196 1,936 2,565

Manufacturing facility

Fully-integrated & automated complex FY21 FY22 FY23 FY24 FY25 # Chlor-Alkali : Caustic Soda - 400 KTPA and Caustic Potash - 21 KTPA Derivatives : CPVC Resin – 75 KTPA, Epichlorohydrin – 50 KTPA, Chloromethanes - 50 KTPA and Hydrogen Peroxide - 60 KTPA Our Journey FY 2007 FY 2010 FY 2015 FY 2017 FY 2020 Epigral Ltd (MFL) incorporated Commissioned 1st Plant • Caustic Soda – 119 KTPA • CPP – 40 MW Increased capacity to • Caustic Soda – 167 KTPA • CPP – 60 MW Commissioned • Caustic Potash – 21 KTPA Commissioned • Chloromethanes – 50 KTPA Converted all Membrane to Zero Gap FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 Commissioned • Hydrogen Peroxide – 60 KTPA Listed as an independent entity on 18th August 2021 Commissioned • Epichlorohydrin – 50 KTPA • CPVC Resin – 30 KTPA Renamed company from Meghmani Finechem to Epigral Increased capacity to • Caustic Soda – 294 KTPA • CPP 96 MW Awarded “Responsible Care” Certificate Increased capacity to Caustic Soda – 400 KTPA CPP – 132 MW Commissioned • 18.

Integration

o Scale up capacities in existing products o New value added products in existing value chains o Improved market position Opportunities in high growth sectors: o Explore opportunities in various sectors o Increase presence & improve market share o Entering into products which are fully imported

New Value Chains

o Expand chemistry expertise to enter new value chains (specialty chemicals) o Addition of new reaction capabilities Achieving economies of scale: o Optimising existing complex o Achieving efficiency operations to become a low cost producer Historical numbers Financial Performance – P&L Revenue (₹ Crore) EBITDA (₹ Crore and %) PAT (₹ Crore and %) 2,565 32% 33% 2,196 1,936 1,555 831 509 261 28% 711 31% 689 25% 481 16% 16% 12% 10% 353 253 196 14% 357 101 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 Margin -% Balance Sheet Ratios ROCE (%)# ROE (%) Net Debt/EBITDA (x) 32% 29% 25% 39% 36% 16% 17% 16% 17% 23% 2.1 1.9 2.0 1.3 0.7 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 FY2021 FY2022 FY2023 FY2024 FY2025 #Capital employed in ROCE includes Capital Work in Progress Historic Income Statement Particulars (₹ Cr) FY2021 Total Revenue Gross Profit Gross Margin (%) EBITDA EBITDA Margin (%) Depreciation Finance Co